Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

Abbott Bioabsorbable Stent  Absorb
Feature

September 28, 2012 — The world’s first drug-eluting bioabsorbable vascular scaffold has been launched and will ...

Home September 28, 2012
Home
Abbott bioresorbable Absorb stent BVS
Feature

September 26, 2012 — Abbott Vascular this week began its international launch of the Absorb coronary stent, the world's ...

Home September 26, 2012
Home
News

August 14, 2012 — The U.S. Food and Drug Administration (FDA) is hosting a public workshop that examines use of ...

Home August 14, 2012
Home
News

July 17, 2012 — Arterial Remodeling Technologies (ART) reported that they have achieved a medical milestone with its ...

Home July 17, 2012
Home
News

July 16, 2012 — Reva Medical Inc. announced it completed clinical enrollment with the ReZolve drug-eluting bioresorbable ...

Home July 16, 2012
Home
News

April 16, 2012 - 480 Biomedical announced that it has initiated the first human trial of its groundbreaking Stanza self ...

Home April 16, 2012
Home
News

April 5, 2012 — Arterial Remodeling Technologies (ART) reported yesterday that in vivo data strongly suggest that its ...

Home April 05, 2012
Home
Feature

March 27, 2012 — Biodegradable polymer drug-eluting stents (DES) provide better long-term safety and efficacy than ...

Home March 27, 2012
Home
Feature | Mark Paquin

April 15, 2012, will mark the 10th anniversary of the approval of the first drug-eluting stent (DES). Ten years ago, the ...

Home March 16, 2012
Home
News

December 22, 2011 ­– Abbott today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe ...

Home December 22, 2011
Home
News

December 9, 2011 — Abbott announced Thursday the initiation of ABSORB II, the first randomized, controlled, multi-center ...

Home December 09, 2011
Home
News

November 15, 2011 – Abbott announced positive long-term data from the two-stage ABSORB trial, which is evaluating the ...

Home November 15, 2011
Home
News

November 7, 2011 – Abbott announced the company's schedule of key data presentations at the 23rd annual Transcatheter ...

Home November 07, 2011
Home
News

November 7, 2011 – Arterial Remodeling Technologies (ART) reported that in vivo data strongly suggest that its second ...

Home November 07, 2011
Home
News

October 24, 2011 — BioCrossroads’ Indiana Seed Fund has announced its twelfth investment, committing $300,000 to medical ...

Home October 24, 2011
Home
Subscribe Now